Palo Alto Investors as of June 30, 2013
Portfolio Holdings for Palo Alto Investors
Palo Alto Investors holds 32 positions in its portfolio as reported in the June 2013 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
---|---|---|---|---|---|
Onyx Pharmaceuticals | 13.6 | $115M | 1.3M | 86.82 | |
ViroPharma Incorporated | 13.4 | $114M | 4.0M | 28.65 | |
Cyberonics | 11.4 | $97M | 1.9M | 51.96 | |
United Therapeutics Corporation (UTHR) | 7.0 | $59M | 901k | 65.82 | |
Abiomed | 5.9 | $50M | 2.3M | 21.56 | |
Auxilium Pharmaceuticals | 5.6 | $47M | 2.8M | 16.63 | |
BioMarin Pharmaceutical (BMRN) | 5.2 | $44M | 787k | 55.74 | |
AMAG Pharmaceuticals | 4.4 | $37M | 1.7M | 22.25 | |
Cubist Pharmaceuticals | 4.3 | $37M | 757k | 48.29 | |
Sequenom | 4.1 | $35M | 8.2M | 4.21 | |
STAAR Surgical Company (STAA) | 3.8 | $33M | 3.2M | 10.15 | |
Questcor Pharmaceuticals | 3.7 | $32M | 696k | 45.44 | |
Vanda Pharmaceuticals (VNDA) | 2.3 | $19M | 2.4M | 8.08 | |
Alimera Sciences | 2.1 | $18M | 3.6M | 4.88 | |
Momenta Pharmaceuticals | 2.1 | $18M | 1.2M | 15.06 | |
InterMune | 2.0 | $17M | 1.8M | 9.62 | |
Rigel Pharmaceuticals | 1.6 | $13M | 3.9M | 3.34 | |
Amicus Therapeutics (FOLD) | 1.3 | $11M | 4.6M | 2.33 | |
Anacor Pharmaceuticals In | 1.1 | $9.0M | 1.6M | 5.59 | |
AVEO Pharmaceuticals | 1.0 | $8.8M | 3.5M | 2.50 | |
Qlt | 1.0 | $8.6M | 2.0M | 4.39 | |
Savient Pharmaceuticals | 0.6 | $5.5M | 9.7M | 0.56 | |
Insmed (INSM) | 0.4 | $3.2M | 266k | 11.96 | |
Aegerion Pharmaceuticals | 0.4 | $3.1M | 49k | 63.34 | |
Cytokinetics | 0.4 | $3.0M | 262k | 11.57 | |
Spectrum Pharmaceuticals | 0.3 | $3.0M | 396k | 7.46 | |
Kythera Biopharmaceuticals I | 0.3 | $2.3M | 86k | 27.05 | |
XOMA CORP Common equity shares | 0.2 | $1.9M | 523k | 3.63 | |
Hyperion Therapeutics | 0.2 | $1.8M | 84k | 22.00 | |
Prothena (PRTA) | 0.1 | $1.1M | 89k | 12.92 | |
Dendreon Corporation | 0.1 | $856k | 208k | 4.12 | |
NxStage Medical | 0.1 | $630k | 44k | 14.28 |